BioSpace News Archive

The global Microbial and Bacterial Cellulose Production market was valued at USD 506.8 Million in 2020 and is expected to reach USD 980.9 Million by 2030, at a CAGR of 8.1%.

Gelesis Holdings today reported financial results for the third quarter of 2022.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended September 30, 2022 and provide a business update on its conference call today.

Windtree Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.

Mindset Pharma Inc. today announced data from preclinical studies comparing its novel prodrug of psilocin, MSP-1014.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase 1/2 clinical trial of intravitreal 4D-150 for wet AMD.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Aerovate Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2022, and recent business highlights.

SELLAS Life Sciences Group, Inc. today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).

EVERSANA ®, a pioneer of next-generation commercial services to the global life sciences industry, today named Sy Pretorius as the company’s new Chief Operating Officer and President, Outsourced Solutions.